托福格利弗洛辛对肝脏结果的影响:系统性审查
Mani Pathak1, Rizwana Parveen1, Parvej Khan1
1Centre for Translational and Clinical Research, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, 110062, India.
托福格利弗洛辛在2型糖尿病患者中显著改善了肝功能标志物,这些患者患有非酒精性脂肪肝疾病. 需要进一步的研究来证实它对肝脏结果的有效性.
科学领域:
- 内分泌学和肝病学 在内分泌学和肝病学.
- 药理学研究 药理学研究
背景情况:
- 非酒精性脂肪性肝病 (NAFLD) 在2型糖尿病 (T2DM) 患者中非常普遍.
- 了解T2DM肝脏健康的治疗效果至关重要.
结论:
- 托福格利弗洛辛在患有肝脏疾病的T2DM患者的肝脏参数有所改善.
- 需要进行更广泛的临床试验,以确定托福格利弗洛辛对T2DM肝脏结局的最终疗效.
更多相关视频
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
Hepatic Drug Excretion: Influencing Factors
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: Sulfonylureas
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
